Interventional Cardiology
ST-elevation MI treatment and primary PCI
Also called ST elevation MI, primary PCI, STEMI protocol
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Where experts stand
Where verified peers stand
Peer votes count verified clinicians only (n=0). As of Nov 21, 2026.
Unverified · drafted by AI from the sources cited below
ST Elevation Myocardial Infarction (STEMI) is a clinical syndrome defined by symptoms of myocardial ischemia, persistent elevation in the ST segments of an electrocardiogram, and the release of biomarkers indicating myocardial necrosis, such as elevated troponin levels.1
The current STEMI/NSTEMI framework may not fully capture all patients with acute coronary occlusion who present without diagnostic ST-segment elevation.1 Furthermore, a proposed alternative is the Occlusion/Non-Occlusion Myocardial Infarction (OMI/NOMI) framework.1 Various OMI definitions have been assessed; for instance, among 6,558 patients with acute coronary syndromes, OMI frequency varied from 37.8% (using culprit artery TIMI flow grade 0) to 76.1%.2 Another potential issue related to diagnosis and risk is contrast-associated acute kidney injury, which occurred in 139 patients (15.4%) within 48 to 72 hours after primary percutaneous coronary intervention (PCI) among 903 STEMI patients in a retrospective cohort.3 Additionally, new-onset in-hospital heart failure remains a significant complication for patients with type 2 diabetes mellitus complicated by STEMI who undergo emergency PCI.4
Prompt myocardial revascularization using primary PCI is essential for myocardial salvage and improving patient outcomes in STEMI.12 Between 2003 and 2018 in Western Denmark, the 1-year mortality rate for patients undergoing primary PCI decreased gradually from 10.8% in 2003-2006 to 7.7% in 2015-2018.3 For STEMI patients with multivessel disease, complete revascularization is recommended.4 In terms of pharmacotherapy, early initiation of evolocumab 140 mg biweekly plus atorvastatin 20 mg/day was tested in STEMI patients undergoing primary PCI for 12 weeks.5
The exact role of hemorrhage in reperfusion-mediated myocardial infarction expansion remains a subject of ongoing investigation.1 Also, survivors of acute coronary syndromes continue to face an elevated risk of recurrent atherosclerosis-related vascular events, and the underlying causes of this sustained proatherogenic state remain unclear.2
Determinants of Pre-Hospital Delay in Patients with ST-Elevation Myocardial Infarction in Dera Ismail Khan
Journal of College of Physicians And Surgeons Pakistan — Khan M — Nov 2026
Association of ALI and mCONUT With In‐Hospital De Novo Heart Failure in Patients With STEMI
Clinical Cardiology — Dai Z — Nov 2026
CCU #bruinhearts Journal Club: TOMAHAWK
UCLA #bruinhearts — Tue, Sep 1, 3:00 PM EDT
CCU Journal Club: PLATO Trial
UCLA #bruinhearts — Tue, Jul 28, 3:00 PM EDT — 5 attended
Sessions from public communities on Synapse. RSVP to join the live discussion.
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology — Broch K
470 citations · 2021 · among the most cited on STEMI management
Reperfusion Injury in Patients With Acute Myocardial Infarction
Journal of the American College of Cardiology — Welt F
274 citations · 2024 · among the most cited on STEMI management
Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis
European Heart Journal — Dong Z
137 citations · 2023 · among the most cited on STEMI management
Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology — Thrane P
110 citations · 2023 · among the most cited on STEMI management
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Annals of Noninvasive Electrocardiology — Macedo D — Oct 2026
The evidence sections above show what the literature supports; this is what the field is still arguing about. Open a debate for the camps, the named voices, and the vote.
Intramyocardial Hemorrhage and the “Wave Front” of Reperfusion Injury Compromising Myocardial Salvage
Journal of the American College of Cardiology — Liu T
105 citations · 2022 · among the most cited on STEMI management
Across this topic’s most recent indexed papers.